Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) EBITDA Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBITDA Margin for 2 consecutive years, with 58915.04% as the latest value for Q2 2025.

  • Quarterly EBITDA Margin changed N/A to 58915.04% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 27.84% through Dec 2025, changed N/A year-over-year, with the annual reading at 1.29% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q2 2025 was 58915.04% at Neuphoria Therapeutics, up from 73.78% in the prior quarter.
  • The five-year high for EBITDA Margin was 58915.04% in Q2 2025, with the low at 487.66% in Q4 2024.